Pressure BioSciences Shatters Preconceived Nanoemulsion Stability, Performance, and Production Limits: Produces CBD Oil Nanoemulsions with 18 Month Stability

Pressure BioSciences breaks the stability, performance and preconceived production limits of the nanoemulsion: produces CBD oil nanoemulsions with a stability of 18 months

The ultra-low droplet sizes of the UST platform and the verified stability of the tests suggest a revolution in the main markets

SOUTH EASTON, MA / ACCESSWIRE / December 22, 2021 / Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or “the company”), a leader in the development and sale of innovative pressure-based instruments, consumables and services widely enabling biotechnology, biotherapy, cosmetics worldwide . , nutraceuticals, agrochemicals and the food and beverage industries, announced today that hemp-derived cannabidiol (“CBD”) processed with its patented Ultra Shear Technology ™ (“UST ™”) platform produced CBD oil nanoemulsions. water-soluble high-quality water that has now demonstrated solid visual and analytical stability as rock 18 months after production and benchmark tests.

CBD is a very popular therapy to relieve anxiety, depression and PTSD, as well as chronic and neuropathic inflammatory pain. It is approved by the FDA for use in the control of epileptic seizures in Lennox-Gastaut Syndrome and Dravet Syndrome. Early research suggests that CBD reduces spasticity in multiple sclerosis and may reduce the severity of neurological symptoms associated with Alzheimer’s disease, Parkinson’s disease, and schizophrenia. CBD is being investigated as a complementary palliative therapy in cancer.

However, CBD is insoluble in water and is poorly absorbed by the human body. The World Health Organization (WHO) estimates that only 6% of CBD is absorbed through current oral delivery routes. Thus, most of the ingested CBD is wasted, passing through the body without being absorbed. Consequently, there is a huge interest in the development of truly water-soluble CBD to provide efficient dosing, absorption, bioavailability, and benefit from CBD products (e.g., food and beverages, therapeutics).

Dr. Alexander V. Lazarev, Scientific Director of PBI, explained: “Solid lipid nanoemulsions, liposomes and nanoparticles present many interesting opportunities as pharmaceutical and nutraceutical delivery systems. The smaller the size of the droplets or particles of oil, the better the stability and bioavailability: once the droplets / particles reach below 100 nanometers, the nanoemulsions appear optically clear and remain stable for months or even years, thus maintaining their aesthetic appeal, bioavailability. and, above all, its shelf life.In addition, these preparations can be filtered-sterilized to meet FDA requirements for injectable drugs.Today we are pleased to announce that our UST process has been shown to be accessible, affordable and scalable, it creates nanoemulsions that maintain rock-solid stability, excellent water solubility, and pristine visual clarity in the room. for at least 18 months. These results offer the potential to significantly increase the shelf life and effectiveness of CBD and a host of other oil-based products currently in use. ”

Mr. Gary B. Smejkal, senior research scientist at PBI, explained the company’s progress: “The intense fluid shear at UST is progressively decreasing the size of the oil droplets with each cycle, making the method very adjustable while allowing the user to reliably select and achieve a target droplet size We have shown that our platform constantly produces CBD nanoemulsions of uniform droplet sizes of 30-40 nm that are stable at room temperature for At least 18 months Measurements of droplet size by dynamic light scattering (DLS) over time at different temperatures have shown that particle size remains unchanged during prolonged storage at room temperature or refrigeration, an important indication of the stability of the nanoemulsion The clarity, quantified by UV / Vis spectroscopy, also remains unchanged for equally long periods of time, making the nanoemulsion of C BD is visually undetectable when infused. in bottled water or other beverages “.

To watch a short video of PBI’s innovative UST platform for CBD nanoemulsion preparation, click here.

Mr. John B. Hollister, PBI’s Director of Sales and Marketing, predicted: “CBD oil nanoemulsions created by our patented UST processing platform offer the potential to revolutionize the rapidly growing cannabis market in food / beverage and But CBD is just a microcosm of the revolution, we believe the UST platform promises to offer a wide range of products covering a variety of important markets, such as therapeutics, nutraceuticals, agrochemicals, cosmetics and food / beverages. of truly clear and water-soluble infusions in long-lasting beverages – long-term stability (cold or room temperature), up to a predictable dosage with a much faster onset of action than other oral / topical forms, we believe that the Consumer benefits, attractiveness and adoption will be huge, with a record milestone of more than 18 months of stability. of customers of our UST nanoemulsion systems after the commercial launch scheduled for the first half of 2022 “.

With a projected compound annual growth rate (CAGR) of 21.2% from 2021 to 2028, the global CBD market is expected to grow from $ 2.8 million in 2020 to $ 13 million in 2028.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, widely enabled and pressure-based solutions for the life sciences and other industries worldwide. Our products are based on the unique properties of constant (i.e., static) and alternating (i.e., pressure cycle or PCT) hydrostatic pressure. PCT is a patented technology platform that uses alternating hydrostatic pressure cycles between ambient levels and high altitudes to monitor biomolecular interactions in a safe and reproducible manner (e.g., cell lysis, biomolecule extraction). Our main focus is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutic characterization and quality control, soil and plant biology, forensics and bioterror applications. In addition, significant new market opportunities have arisen in the use of our pressure-based technologies in the following areas: (1) the use of our newly acquired patented technology from BaroFold, Inc. (“BaroFold” technology) to enable entry into the biopharmaceutical contract services industry, and (2) the use of our recently patented, scalable, high-efficiency Ultra Shear (“UST”) technology platform and pressure-based to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare stable, high-quality, homogeneous, liquid, low-acid foods at room temperature. of extended service life or which cannot be effectively preserved by existing non-thermal technologies.

Prospective statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve risks, uncertainties and other known and unknown factors that may substantially result in the actual results, activity levels, performance or achievements of our industry or industry. different from future results or levels. of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you may identify forward-looking statements by terminology such as “may”, “should”, “should”, “could”, “would be”, “wait”, “plan”, “intend”, “anticipate”. “” believes “,” estimates “,” predicts “,” projects “,” potential “or” continues “or the negative of these terms and other comparable terminology. These statements are only predictions based on our current expectations and projections of future events. You should not unduly trust these statements. When evaluating these statements, you should specifically consider several factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statements. risks, uncertainties and other factors include, but are not limited to, the risks and uncertainties addressed under “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 and other reports submitted. by the Time Company and I’m with the SEC. The company assumes no obligation to update any of the information included in this release, unless otherwise provided by law.

For more information on GDP and this press release, click on the following website link:
http://www.pressurebiosciences.com
Visit us on Facebook, LinkedIn and Twitter.

Press contacts:

Richard T. Schumacher, Chairman and Chief Executive Officer (508) 230-1828 (T)
Jeffrey N. Peterson, President (650)703-8557 (T)
Alexander V. Lazarev, Ph.D. Scientific Director (508) 230-1828 (T)

SOURCE: Pressure BioSciences Inc.

View the source version on accesswire.com:
https://www.accesswire.com/679117/Pressure-BioSciences-Shatters-Preconceived-Nanoemulsion-Stability-Performance-and-Production-Limits-Produces-CBD-Oil-Nanoemulsions-with-18-Month-Stability

Published December 22, 2021

No related posts.